Citigroup
RARE icon

Citigroup’s Ultragenyx Pharmaceutical RARE Stock Holding History

Citigroup’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,700
Closed -$472K – 6389
2025
Q3 		$472K Buy
+15,700
New +$471K ﹤0.01% 3610
2025
Q2 		– Sell
-29,900
Closed -$1.08M – 5857
2025
Q1 		$1.08M Sell
29,900
-16,100
-35% -$670K ﹤0.01% 3195
2024
Q4 		$1.94M Buy
46,000
+30,000
+188% +$1.49M ﹤0.01% 2849
2024
Q3 		$889K Buy
+16,000
New +$815K ﹤0.01% 3351
2024
Q1 		– Sell
-74,500
Closed -$3.56M – 5815
2023
Q4 		$3.56M Buy
74,500
+54,300
+269% +$2.11M ﹤0.01% 1821
2023
Q3 		$720K Sell
20,200
-9,700
-32% -$384K ﹤0.01% 2778
2023
Q2 		$1.38M Sell
29,900
-25,000
-46% -$1.16M ﹤0.01% 2557
2023
Q1 		$2.2M Sell
54,900
-22,800
-29% -$978K ﹤0.01% 1954
2022
Q4 		$3.6M Buy
+77,700
New +$3.06M ﹤0.01% 1662
2020
Q2 		– Sell
-7,500
Closed -$333K – 7649
2020
Q1 		$333K Sell
7,500
-5,300
-41% -$275K ﹤0.01% 4247
2019
Q4 		$547K Buy
12,800
+7,600
+146% +$314K ﹤0.01% 4351
2019
Q3 		$222K Sell
5,200
-800
-13% -$43.5K ﹤0.01% 5064
2019
Q2 		$381K Buy
6,000
+700
+13% +$44.6K ﹤0.01% 4690
2019
Q1 		$368K Buy
5,300
+4,000
+308% +$229K ﹤0.01% 4508
2018
Q4 		$57K Sell
1,300
-2,900
-69% -$158K ﹤0.01% 6127
2018
Q3 		$321K Buy
4,200
+2,700
+180% +$220K ﹤0.01% 4765
2018
Q2 		$115K Sell
1,500
-2,000
-57% -$129K ﹤0.01% 5590
2018
Q1 		$178K Sell
3,500
-2,200
-39% -$111K ﹤0.01% 5083
2017
Q4 		$264K Buy
5,700
+3,600
+171% +$177K ﹤0.01% 4780
2017
Q3 		$112K Sell
2,100
-4,000
-66% -$237K ﹤0.01% 5471
2017
Q2 		$379K Sell
6,100
-2,500
-29% -$151K ﹤0.01% 4244
2017
Q1 		$583K Sell
8,600
-1,500
-15% -$114K ﹤0.01% 3734
2016
Q4 		$710K Buy
10,100
+9,500
+1,583% +$674K ﹤0.01% 4028
2016
Q3 		$43K Buy
+600
New +$38.3K ﹤0.01% 5763

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Citigroup's RARE Position: Q1 2026 in Review

Citigroup increased its Ultragenyx Pharmaceutical (RARE) stake by 354% in Q1 2026, buying an estimated $5.54M and bringing the position to 315,440 shares worth $6.61M. The position accounts for ﹤0.01% of the portfolio, ranked #1753.

Citigroup first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $9.07M in Q4 2016. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Citigroup held 315,440 shares of Ultragenyx Pharmaceutical worth $6.61M as of Q1 2026.
  • Citigroup bought 245,929 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $5.54M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #1753 holding.
  • Citigroup first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
  • Citigroup's Ultragenyx Pharmaceutical position peaked at $9.07M in Q4 2016.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.